NTRA News and Press, Natera Inc. From 05/08/23

2023-05-08 17:35:56 ET Major earnings expected after the bell on Tuesday include: Airbnb ( ABNB ) Occidental Petroleum Corporation ( OXY ) Twilio ( TWLO ) Virgin Galactic Holdings ( SPCE ) Upstart Holdings ( UPST ) For further details see: ...

Study with 283 patients, >1,000 plasma samples, and longest follow-up exceeding 5 years demonstrates how ctDNA monitoring can help inform treatment decisions in HR+/HER2- and TNBC patients Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2023, after the market close on May 9, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET)...

Includes long-term follow-up data (>5 years) in patients with muscle-invasive bladder cancer and additional studies in colorectal, gastroesophageal and hepatocellular carcinoma Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its ...

Real-world findings from >550 plasma samples highlight prognostic and predictive value of Signatera for adjuvant decision-making and immunotherapy monitoring Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Cancer ...

2023-03-15 11:31:39 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent rel...

2023-03-08 14:14:51 ET The following slide deck was published by Natera, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Natera, Inc. 2022 Q4 - Results - Earnings Call Presentation

Summary Cutting the cash burn and other operational expenses should bring back Natera, Inc. financial health. Natera produced in 2022 loads of peer-reviewed ammunition for winning more and more market share in women's health, oncology, and organ transplant. Recent and upcoming studi...

Texas-based molecular diagnostic company Natera ( NASDAQ: NTRA ) announced first commercial coverage policies for its cancer screening test, Signatera, on Thursday. The company said that Blue Shield of California has decided to cover it for plan members diagnosed with solid tumors for...

Pan-cancer policy from Blue Shield of California covers adjuvant, recurrence monitoring, and treatment monitoring Multi-cancer policy from BCBS of Louisiana covers CRC, Bladder, and IO monitoring Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today an...